FDA Compares New Products' DTC Ads To Competitor Campaigns
This article was originally published in The Pink Sheet Daily
Executive Summary
If two products have similar risks and claims, their advertisements should include similar presentations, FDA DTC review group leader Moncavage suggests. Companies can learn how to design ads by assessing the letters FDA sends to violators, she says.